PHVS jumps after positive topline HAE trial results
Pharvaris (PHVS) shares rose after the company disclosed positive topline data from a hereditary angioedema (HAE) trial. The stock gained 11% to $39.26 on Tuesday.
26 on Tuesday. The Swiss biopharmaceutical company said its…